logo
Shock jobs report stirs recession fears: 5 takeaways

Shock jobs report stirs recession fears: 5 takeaways

USA Todaya day ago
The disappointing July jobs report threw a bucket of cold water on an economic outlook that appeared to be holding up surprisingly well despite President Donald Trump's high import tariffs, immigration crackdown and widespread federal layoffs.
Not only did employers add a disappointing 73,000 jobs – well below the 105,000 expected – but payroll gains for May and June were revised downward by a whopping 258,000. That left May's additions at 19,000 and June's at 14,000, the weakest performance since the nation was climbing out of the COVID-19 recession in December 2020.
In early afternoon trading, the Dow Jones Industrial Average was down about 607 points and the benchmark S&P 500 index was off 1.5%
Over the past three months, the economy has averaged just 35,000 employment gains.
Here are a few takeaways:
This was no blip
The poor showing likely wasn't an outlier that will be followed by a resumption of healthy job gains in the months ahead, economists said. Consumers have reined in their spending somewhat, amid worries about Trump's tariffs pushing up prices, and are pulling back on travel and recreational activities. As more of the import charges hit store shelves, Americans will likely restrain their outlays further, Pantheon Macroeconomics wrote in a note to clients.
That should translate into weaker job gains, especially in sectors such as manufacturing, retail, trucking and warehousing, the research firm said.
And on July 31, Trump escalated his global trade fight with a sweeping new round of import levies.
Meanwhile, executives' confidence in the business outlook has been shaken in recent months by the tariffs – which are squeezing profit margins – and that's expected to spell a more pronounced decline in business investment, Pantheon said.
'Sadly, employment appears set for a further summer slowdown as firms, facing renewed cost volatility from escalating trade tensions, remain focused on managing labor costs through reduced hiring, performance-based layoffs, restrained wage growth, and lower entry-level wages,' Gregory Daco, chief economist of EY-Parthenon, wrote to clients.
Also, after the Supreme Court recently lifted a stay on mass federal layoffs, 'the decline in federal employment likely will gather more momentum over the coming months,' Pantheon said.
The Labor Department has tracked 84,000 federal job losses this year, but the number of buyouts and job cuts announced was much larger.
Hiring across the economy hit a 12-month low in June, Labor Department figures show.
Will there be a recession in 2025?
The dreaded word has slipped back into the conversation after fading the past couple of months as Trump delayed many tariffs and reached deals with several countries.
'To me, today's jobs report is what entering a recession looks like,' Josh Bivens, chief economist of the left-leaning Economic Policy Institute, said in a statement. 'Could we pull up? Sure. But if we look back and end up dating an official recession that starts 3-6 months from now, this is what it would look like today – rapid softening/deterioration in the labor market.'
A recession now appears 'very, very likely' unless Trump lowers the tariffs by Labor Day, said Mark Zandi, chief economist of Moody's Analytics.
Could a skidding economy and stock market lead Trump to reverse course?
A darkening economic outlook and tumbling stock market could well prompt Trump to try to soften the import fees, Zandi said. 'He's going to try to pull it back,' he said.
But if he doesn't act before Labor Day, 'It will be too late,' Zandi said, adding the duties will start to ripple too dramatically into retail prices and consumer and business sentiment for the effects to be undone.
A September fed rate cut likely
At a July 30 news conference following the Fed's decision to hold rates steady for a fifth straight meeting, Fed Chair Jerome Powell described the labor market as solid and balanced. He also said officials would focus primarily on the unemployment rate as they decide whether to lower rates in September.
The jobless rate edged up to 4.2% in July. It's still historically low even as Trump's immigration constraints, particularly deportations, shrank the labor force – the pool of people working or looking for jobs. Still, employer demand for employees has waned.
But Morgan Stanley suggested the feeble job gains of the past three months would spur the Fed to act in September despite stable unemployment.
'The slower payroll pace keeps downside risks elevated and a September cut on the table,' Morgan Stanley said in a research note.
Fed fund futures markets are now putting the chances of a September rate decrease at 85%, up from 45% after Powell's July 30 remarks.
AI is starting to crimp job gains
Professional and business services shed 14,000 jobs in July and payroll gains in the sprawling white-collar sector have been stagnant for more than two years. July's showing included job losses in computer and technical roles. Staffing executives say companies are replacing many entry-level information technology workers with artificial intelligence.
'It is happening,' Goldman Sachs chief economist Jan Hatzius said on CNBC after the release of the July jobs report. 'This is not the main thing driving the labor market... But we're seeing early signs.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Senate makes progress in averting a gov't shutdown much earlier than usual
Senate makes progress in averting a gov't shutdown much earlier than usual

New York Post

time16 minutes ago

  • New York Post

Senate makes progress in averting a gov't shutdown much earlier than usual

The Senate took a significant step towards averting an impending partial government shutdown by passing a tranche of funding bills much earlier than usual. Senators approved three of the 12 appropriations bills Friday needed to forestall a partial shutdown, including ones to fund the Department of Veterans Affairs, the Food and Drug Administration, the Department of Agriculture, new military facilities, and Congress itself. 'We are on the verge of an accomplishment that we have not done since 2018, and that is, pass appropriations bills across the Senate floor prior to the August recess,' Senate Appropriations Committee Chairwoman Susan Collins (R–Maine) cheered before the upper chamber reached the feat. 'That is exercising our constitutional responsibility for the power of the purse.' The three appropriations bills that clear the Senate are typically viewed as the less controversial ones to get across the finish line. Still, it comes amid significant hurdles toward preventing the looming autumn shutdown. 4 Sen. Susan Collins helped broker the deal to get the three appropriations bills passed through the Senate. REUTERS 4 Senate Majority Leader John Thune has eaten into the August recess to clear up the upper chamber's lengthy to-do list. Democrats widely see the shutdown fight as a rare instance in which they have leverage in Congress and have been vexed by President Trump's use of impoundment and rescissions to make spending cuts without their approval. Moreover, Congress hasn't actually passed the 12 appropriations bills to properly fund the government on time since 1997. Each fiscal year, which starts on Oct. 1, Congress is tasked with funding the government to prevent a partial shutdown. Congress has typically relied on a mechanism known as continuing resolutions, or CRs, to put government spending on autopilot for stretches of time. CRs and appropriations bills are subject to the 60-vote threshold needed to break a filibuster in the Senate and must be bipartisan, which is why Congress typically struggles with the process. 4 Sen. Patty Murray said the deal will help prevent some of the cuts Democrats opposed. The current fiscal year is running on what turned into a yearlong CR, and there have been some murmurs in the House about doing so again for Fiscal Year 2026. Senators voted 87-9 on Friday for a two-bill minibus to fund the VA and Department of Agriculture. They then voted 81–15 on the third appropriations bill to fund Congress. Sen. Patty Murray (D-Wash.), the top Democratic appropriator, argued the small-scale deal 'rejects damaging cuts from Trump and House Republicans,' despite progressive complaints. The Senate still has nine more appropriations bills to take up: Commerce, Defense, Energy, Financial Services, Homeland Security, Interior, Labor, State and Transportation. The Senate Appropriations Committee has already approved about half of those, inching them closer to a full chamber vote. 4 Oftentimes, government shutdown fights come down to the wire. REUTERS Those appropriations bills will need to be green-lit by the House of Representatives, which is on August recess, and signed into law by President Trump. Senate Majority Leader John Thune (R-SD) has eaten into the August recess while seeking to wrangle through key Trump nominations and chip away at the backlog. He is currently negotiating with Democrats on a deal to expedite that process.

Trump should heed, not hide, the jobs numbers
Trump should heed, not hide, the jobs numbers

Washington Post

time17 minutes ago

  • Washington Post

Trump should heed, not hide, the jobs numbers

Here's a life hack for readers who are trying to lose weight and are discouraged by the numbers on the scale: Take a hammer to the thing. If that seems too destructive, donate it to the Salvation Army and, if you must keep a scale in the house, buy a new model that tops out at 150 pounds. The secret behind this hack is psychology. It's hard to eat less than your body wants, which is why people who try to lose weight often fail and feel miserable. But if no working scale is available, you can't fail: Eat as much as you like; the numbers will never climb. Sound crazy? It is. But the president has just used a version of this trick to deal with a sagging American jobs market. For months, commentators have been asking why tariffs aren't weighing on the economy more heavily. Importers — including many manufacturers — have been worried that they will. But the headline jobs and gross domestic product data have looked pretty good. Then came Friday's jobs report. The Bureau of Labor Statistics, a unit of the Labor Department, revised its estimates for May and June payrolls sharply downward, by more than 250,000 jobs, and estimated that the economy added only 73,000 jobs in July, well below analysts' expectations. Virtually all these new jobs came from health care and social services. The numbers contain no sign of the manufacturing boom that President Donald Trump has promised. This is not the sort of jobs report any president wants to see; it's the kind that portends falling approval ratings and party losses at the next election. So Trump took immediate, decisive action: He hopped on Truth Social and announced that he would fire Erika McEntarfer, the commissioner of the Bureau of Labor Statistics. This move was so boneheaded, William Beach, who served as bureau commissioner during the first Trump administration, called it 'totally groundless' and 'a dangerous precedent' that 'undermines the statistical mission of the Bureau.' A hearty second to that. Trying to intimidate the Bureau of Labor Statistics is the policy equivalent of smashing your bathroom scale. It's banana republic stuff, and it won't work any better in the United States. On the margin, a few voters might be fooled into thinking economic conditions are better than they really are. But the trick can work only so far — as the Biden administration found out when it tried to gaslight voters into believing that everything in the White House was going just great. The people most susceptible to the spin fall into two groups: the president's base, who don't need it, and high-information voters who pay close attention to economic data, many of whom will understand how the numbers have been juked, and most of whom probably already know which side they're voting for next time around. Everyone will be paying closer attention to what's happening in their own experience. Are wages rising? Are their friends and relatives being laid off? Is it easy to find another job? If they're getting the wrong answers to these questions, it really doesn't matter what numbers the bureau is putting out. That is, it doesn't matter politically. Bureau of Labor Statistics numbers matter tremendously in other ways. They feed into a great deal of market activity as well as vital social science, both of which are possible only if the numbers are trustworthy. The statistics are also, of course, one of the president's essential guides to economic policy. This guide is now telling the administration that it is moving in the wrong direction. A wise politician would take heed and course-correct to avoid bumbling deeper into the woods. Instead, Trump wants to shoot the messenger so his supporters won't realize he's led them astray. He might be able to find a new BLS commissioner who will cook the numbers to make them more aesthetically pleasing, though this would not be easy. As economist Scott Winship of the American Enterprise Institute pointed out, a lot of people work on these numbers, 'So absent mass firings at BLS, this solves nothing.' But even if Trump managed to bully the guides into telling him what he wants to hear, what then? Eventually voters will look around and notice the truth: America is losing its way.

Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks

Business Insider

time28 minutes ago

  • Business Insider

Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks

There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store